Stock Analiz

Harvard Bioscience Inc. HBIO

Biotechnology: Laboratory Analytical Instruments · IPO 2000 · data as of November 13, 2026

$9.39Market cap $43M
Open the interactive analysis →

Harvard Bioscience Inc. (HBIO) is a industrial company listed in the US with a market value of about $43M. In the twelve months to September 30, 2026 it had revenue of $89M and net income of -$12M, a net margin of -13.2%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 1.1, 5-year revenue growth of -3% a year, a 5-year average ROIC of -18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.

About Harvard Bioscience

Harvard Bioscience is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2000. Revenue went from $109M in 2014 to $87M in 2025, a decline of about 2.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 7% over three years (dilution for shareholders). It spends 10% of revenue on research and development.

Score: 0.8 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)1.1
Forward P/E—
P/FCF—
P/S0.5
P/B8.4
EV/EBITDA19.7
PEG—
Dividend yield0.00%
FCF yield-7.4%
Shareholder yield0.0%
Intrinsic value vs. price−64%

Growth and quality

Revenue growth (1 yr)-8.1%
Revenue growth (5 yrs, per year)-3.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-18.1%
ROIC (5-yr avg.)-17.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$89M$87M$94M$112M$113M$119M$102M$116M$121M$77M$105M
Net income-$12M-$57M-$12M-$3M-$10M-$288000-$8M-$5M-$3M-$865000-$4M
Free cash flow-$3M$5M-$1M$12M-$438000$67000$8M$7M$2M$167000—
EPS (diluted)$8.88$-1.28$-0.28$-0.08$-0.23$-0.01$-0.20$-0.12$-0.08$-0.02$-0.13
Net margin-13.2%-65.5%-13.2%-3.0%-8.4%-0.2%-7.6%-4.0%-2.4%-1.1%-4.1%
ROIC—-82.7%-4.5%1.3%-4.3%1.2%0.1%0.2%0.4%-0.5%-2.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Harvard Bioscience’s P/E ratio?

About 1.1, based on the last twelve months of diluted earnings per share.

Is Harvard Bioscience stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Harvard Bioscience pay a dividend?

Not currently.

Is Harvard Bioscience a good stock to buy?

We do not give buy or sell advice. Harvard Bioscience scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.